the pathogenesis of fibrosis and implications for therapy
TRANSCRIPT
![Page 1: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/1.jpg)
Hypersensitivity pneumonitis
Milan, Italy2nd March 2019
Toby Maher MB MSc PhD FRCPBritish Lung Foundation Chair in Respiratory Research and NIHR Clinician ScientistProfessor of Interstitial Lung Disease, National Heart Lung Institute, Imperial College, LondonConsultant Respiratory Physician, Royal Brompton Hospital
![Page 2: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/2.jpg)
Declarations of interest• Board membership/consultancy
• GSK• Boehringer Ingelheim• UCB• Roche• Bayer• Biogen Idec• ProMetic• Apellis• Respivert• PatientsLikeMe
• Lecture Fees• UCB• AstraZeneca• Boehringer Ingelheim• Roche• Cipla
• Clinical Trials• Boehringer Ingelheim• Novartis• GSK• Gilead Sciences• Roche• InterMune• Galecto• Sanofi Aventis
• Grants• GSK • Novartis• UCB
![Page 3: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/3.jpg)
Hypersensitivity pneumonitis - pathogenesis
Selman et al AJRCCM 2012
![Page 4: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/4.jpg)
Acute hypersensitivity pneumonitis
![Page 5: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/5.jpg)
Chronic hypersensitivity pneumonitis
![Page 6: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/6.jpg)
Assessment of suspected HP• History
• Exposure
![Page 7: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/7.jpg)
Selman et al AJRCCM 2012
![Page 8: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/8.jpg)
Assessment of suspected HP• History
• Exposure • But 60% lack clear exposure
• Examination• “Squawks” on auscultation
• Imaging• Acute – centrilobular nodules, ground glass +/- gas trapping• Chronic – fibrosis, mosaicism, bronchocentric distribution
![Page 9: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/9.jpg)
HRCT pointers to chronic hypersensitivity pneumonitis
• Lobules of decreased attenuation in spared (non-fibrotic) lung
• Unusual distribution of fibrosis, particularly vague bronchocentricity in upper lobes
• Coexistent subacute changes - indistinct relatively low attenuation centrilobular nodules (rare)
![Page 10: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/10.jpg)
Lobules of decreased attenuation in spared lung
![Page 11: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/11.jpg)
Unusual distribution of fibrosis, particularly vague bronchocentricity in upper lobes
![Page 12: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/12.jpg)
Chronic hypersensitivity with UIP features
![Page 13: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/13.jpg)
Assessment of suspected HP• History
• Exposure • But 60% lack clear exposure
• Examination• “Squawks” on auscultation
• Imaging• Acute – centrilobular nodules, ground glass +/- gas trapping• Chronic – fibrosis, mosaicism, bronchocentric distribution
• Bronchoscopy• Lymphocytes >?20%
• Biopsy• Airway centred granulomata, chronic cellular bronchiolitis, chronic
interstitial inflammatory cell infiltrate• Blood testing
• Specific circulating antibodies
![Page 14: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/14.jpg)
Case History• 55 year old practising primary care physician• 6 months mild exertional dyspnoea• No exposures• Lifelong non-smoker• No clubbing• Occasional bibasal crepitations
![Page 15: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/15.jpg)
HRCT
![Page 16: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/16.jpg)
Broncho-alveolar lavage
Lymphocytosis
![Page 17: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/17.jpg)
Surgical Lung Biopsy
![Page 18: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/18.jpg)
Surgical Lung Biopsy
![Page 19: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/19.jpg)
Follow up• MDT diagnosis – probable fibrotic hypersensitivity pneumonitis
![Page 20: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/20.jpg)
Follow up• Diagnosis – probable fibrotic hypersensitivity pneumonitis
• Treated with intravenous methylprednisolone followed by prednisolone 10 mg daily, azathioprine 150 mg daily and NAC
• After 12 months, worsening breathlessness and 14% decline in FVC
![Page 21: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/21.jpg)
![Page 22: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/22.jpg)
Follow up• Diagnosis – probable fibrotic hypersensitivity pneumonitis
• Treated with intravenous methylprednisolone followed by prednisolone 10 mg daily, azathioprine 150 mg daily and NAC
• After 12 months, worsening breathlessness and 14% decline in FVC
• Repeat bronchoscopy – 28% lymphocytes
![Page 23: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/23.jpg)
Follow up• Diagnosis – probable fibrotic hypersensitivity pneumonitis
• Treated with intravenous methylprednisolone followed by prednisolone 10 mg daily, azathioprine 150 mg daily and NAC
• After 12 months, worsening breathlessness and 14% decline in FVC
• Repeat bronchoscopy – 28% lymphocytes
• Treatment changed to intravenous cyclophosphamide 600 mg/m2 body surface area every 4 weeks for 6 doses.
![Page 24: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/24.jpg)
Follow up lung function
Date Pred LI Pred UITest 1
01/06/11Test 2
17/01/12Test 3
10/07/12Test 4
23/04/13Test 5
22/04/14 % Pred
FEV1 2.79 4.46 2.98 2.85 2.80 2.50 2.41 66.6
FVC 3.61 5.61 3.77 3.59 3.44 3.08 2.95 64.1
Pred + Azastarted
Cytoxanstarted
![Page 25: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/25.jpg)
Follow up
• Further MDT discussion. Revised diagnosis to probable IPF based on longitudinal disease behaviour
• Treatment started with pirfenidone 801 mg t.i.d.
• Gradual decline in lung function – Dlco 22% predicted
• As of January 2016 on active transplant waiting list
![Page 26: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/26.jpg)
January 2016
January 2016
![Page 27: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/27.jpg)
June 2016
![Page 28: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/28.jpg)
IPF
CTD-ILD
Fibrotic ILD re-visualised
HP
PossibleIPF
SuspectedChronic HP
Interstitial pneumonia with autoimmune features
(IPAF)
![Page 29: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/29.jpg)
Post-2012: A new era in diagnosing and treating pulmonary fibrosis
PROGRESSIVE FIBROSINGLUNG DISEASE
PRE - 2012
UIP NSIP
AIP
ChronicHP
CTD-ILD
IPAF
Treat with steroid ± azathioprine
![Page 30: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/30.jpg)
![Page 31: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/31.jpg)
A new era for IPF
![Page 32: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/32.jpg)
Post-2012: A new era in diagnosing and treating pulmonary fibrosis
PROGRESSIVE FIBROSINGLUNG DISEASE
PRE - 2012
UIP NSIP
AIP
ChronicHP
CTD-ILD
IPAF
PROGRESSIVE FIBROSINGLUNG DISEASE
POST - 2012
Treat with steroid or immunosuppressant
Chronic HPCTD-ILD
IPAF
Treat withanti-fibrotic
IPF
Treat with steroid ± azathioprine
![Page 33: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/33.jpg)
Diagnostic Confidence for Hypersensitivity PneumonitisDefinite
1. Probable/Definite histopathologic likelihood with,a. Antigenic history, ORb. Definite HRCT likelihood, ORb. Probable HRCT likelihood and Lymphocytosis
2. Probable/Definite HRCT likelihood, Lymphocytosis & Antigenic history (absentbiopsy)
Highly Probable1. Probable/Definite HRCT likelihood with,
a. Antigenic history (absent histopathology), ORb. Lymphocytosis (absent histopathology), ORc. Possible histopathologic likelihood with lymphocytosis or antigenic history,
OR,d. Probable histopathologic likelihood
2. Probable/Definite histopathologic likelihood with Lymphocytosis and possible HRCTlikelihood
Probable1. Lymphocytosis & Antigenic history with a possible HRCT likelihood (with at least
possible histopathologic likelihood)2. Lymphocytosis or Antigenic history with a possible histopathologic & HRCT
likelihood3. Lone probable/definite histopathologic likelihood (with at least possible HRCT
likelihood)4. Lone probable/definite HRCT likelihood (with at least possible histopathologic
likelihood)5. Possible histopathologic likelihood with lymphocytosis or Antigenic history (with at
least possible HRCT likelihood)
Defining chronic HP
Salisbury et al AJRCCM 2017
![Page 34: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/34.jpg)
Salisbury et al AJRCCM 2017
![Page 35: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/35.jpg)
![Page 36: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/36.jpg)
Morrisett et al AJRCCM 2018
![Page 37: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/37.jpg)
TREATING CHRONIC HYPERSENSITIVITY PNEUMONITIS
![Page 38: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/38.jpg)
Remove the antigen…
![Page 39: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/39.jpg)
Corticosteroids
![Page 40: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/40.jpg)
Cyclophosphamide
Tashkin NEJM 2006
![Page 41: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/41.jpg)
Brompton cyclophosphamide experience
Disease Number of patients Mortality within one year of first dose
Mean FVC change % following cyclophosphamide
%TLCO change following cyclophosphamide
Period 1 Period 2 Period 1 Period 2 Period 1 Period 2 Period 1 Period 2
Scleroderma 21 12 0% 0% -0.43% -1.37% -0.17% 4.61%
Mixed connective tissue disease
0 4 NA 0% NA 2.88% NA 2.02%
Idiopathic myositides including antisynthetase
8 9 0% 0% 7.22% 11.46% -0.94% 11.25%
Unclassfiable connective tissue disease
32 15 0% 5% -0.81 5.98% -6.45% 0.26%
Chronic hypersensitivity pneumonitis
15 26 26% 19% -8.90% -1.24% 5.83% -5.66%
Unclassifiable interstitial lung disease
8 15 38% 26% 0.97% 2.00% -6.28% -2.73%
Saunders P et al ATS 2017
![Page 42: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/42.jpg)
Mycophenolate mofetil
Fischer et al J Rheumatol 2013
![Page 43: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/43.jpg)
![Page 44: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/44.jpg)
Rituximab
![Page 45: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/45.jpg)
![Page 46: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/46.jpg)
Lota et al Thorax 2013
![Page 47: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/47.jpg)
Deciding whom to treat0.
000.
250.
500.
751.
00
0 20 40 60Time (momths)
BAL stage 1 BAL stage 2
Survival: combined cohort
BAL Lymphocytes > 20% but neutrophils < 10%
Wells au et al (unpublished)
![Page 48: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/48.jpg)
Anti-fibrotic therapy?
![Page 49: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/49.jpg)
Transplant
![Page 50: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/50.jpg)
Current treatment paradigm
Manage disease complications
Immunosuppressant therapy
Manage disease complications
Anti-fibrotic therapy
Idiopathic Pulmonary Fibrosis Fibro-inflammatory ILD
![Page 51: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/51.jpg)
The future treatment of fibrotic ILD?
Manage disease complications
Treat Underlying Cause (where known)
Anti-fibrotic therapy
If disease progression
![Page 52: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/52.jpg)
Summary• Chronic hypersensitivity pneumonitis is frequently challenging
to diagnose
• A proportion of cases overlap with IPF in terms of disease behaviour and outcome
• Absence of lymphocytosis predicts a poorer outcome and response to treatment
• Best therapy remains to be defined but is likely to be corticosteroids +/- immunosuppressant therapy
• The outcome of trials with anti-fibrotic drugs are awaited
![Page 53: The Pathogenesis of Fibrosis and Implications for Therapy](https://reader034.vdocuments.us/reader034/viewer/2022052115/6288a83add695b79036e1e7e/html5/thumbnails/53.jpg)
Questions?